Health Tech

A recent report from Aon forecasts that average healthcare costs will exceed $19,000 per employee by 2027, marking a significant increase of 9.5% year-over-year. This trend is particularly concerning as employers currently shoulder over 80% of health plan expenses, yet employees are also facing rising costs. In 2026, employees are expected to contribute an average of $5,297 towards their coverage, reflecting a 7.9% increase from the previous year. This includes a 6.4% rise in payroll contributions and a 10.2% increase in out-of-pocket expenses, attributed to higher utilization of healthcare services and enrollment in more limited plan options. The report highlights that the sustained rise in healthcare costs is driven by several factors, including an increase in chronic conditions leading to more high-cost claims and the growing reliance on specialty medications, particularly GLP-1 therapies. The adoption of advanced technologies, such as artificial intelligence for clinical documentation, has also contributed to higher medical billing. This marks the fourth consecutive year of near double-digit increases in healthcare costs, indicating a prolonged period of inflation that employers have not faced in decades. As healthcare expenses continue to escalate, nearly half of U.S. employers with 500 or more employees plan to adjust their 2027 offerings, shifting more financial responsibility onto workers. Furthermore, 83% of employers anticipate that rising healthcare costs will necessitate trade-offs with wage increases. Experts suggest that organizations must proactively identify emerging risks and implement targeted strategies to manage costs effectively, as the pressure to maintain affordable benefits while attracting and retaining talent intensifies.

R1, a healthcare revenue cycle management company, has announced its acquisition of Humata Health, a firm specializing in AI-powered prior authorizations. This strategic move aims to streamline the preapproval process for medical treatments, which is often a significant bottleneck in healthcare delivery. By integrating Humata's technology, R1 hopes to automate claims processing and reduce the administrative burden on healthcare providers, ultimately improving their financial outcomes. Humata Health, founded in 2023 by a physician trained at the Mayo Clinic, has developed an AI tool that boasts a 96% first-pass approval rate for prior authorizations. This acquisition is expected to close in the third quarter of 2026, after which Humata's team will work on integrating its solutions into R1's existing revenue cycle platform. R1 currently processes over 600 million transactions annually across a network of 1,000 providers, and the addition of Humata's capabilities is anticipated to enhance its operational efficiency. The prior authorization process has long been criticized for delaying patient care and increasing administrative workloads for providers. However, insurers argue that these preapprovals are essential for controlling costs and ensuring appropriate care. The federal government has also recognized the need for reform, with a rule finalized in 2024 mandating that insurers expedite prior authorization decisions and adopt technology for electronic preapprovals. R1's initiative aligns with these regulatory changes, as it seeks to make real-time prior authorizations a reality, a goal echoed by other IT companies in the sector. As the healthcare landscape evolves, the integration of AI in prior authorizations could significantly impact how providers interact with insurers, potentially leading to faster care delivery and improved patient experiences. R1's acquisition of Humata represents a critical step towards achieving these objectives in the healthcare industry.

Drew Asher, the Chief Financial Officer of Centene, will step down from his position on December 31, 2023, as part of a planned transition before his retirement at the end of 2027. Chris Neczypor, currently the CFO of Lincoln Financial, has been appointed as Asher's successor and will join Centene next month to facilitate a smooth handover. Neczypor brings extensive experience from the finance and insurance sectors, having held various roles at Lincoln Financial since 2018 and previously working as an equity research analyst at Goldman Sachs. This leadership change comes at a pivotal time for Centene, which has faced significant challenges in recent years, including rising medical costs and a decade-low stock price. However, the company has shown signs of recovery, reporting a profit of $1.1 billion in the second quarter of this year, a notable turnaround from a $253 million loss in the same period last year. Asher, who has been with Centene since 2021, expressed pride in the company's ability to navigate unprecedented changes while maintaining a focus on long-term value. The transition in leadership is part of a broader restructuring within Centene, which has recently created new executive roles and made changes to its board of directors. The company has successfully revamped its Affordable Care Act (ACA) business to address higher spending and market turbulence, leading to improved profitability among its remaining members. Additionally, while Medicaid membership has decreased, Centene has managed to control medical costs effectively, with states reportedly increasing payment rates to better align with member acuity. This strategic shift positions Centene for continued growth and transformation in the healthcare landscape.

A recent survey conducted by Deloitte highlights a significant gap between the expectations placed on healthcare CFOs and their preparedness to meet those expectations. The survey, which included responses from 64 CFOs across health plans and health systems, found that 73% of CFOs are expected to be heavily involved in critical enterprise decisions, such as consumer affordability and mergers and acquisitions. However, only 49% of these finance leaders feel adequately equipped to contribute effectively to these decisions, resulting in an alarming average gap of 24 percentage points. The report emphasizes that as financial pressures mount within the healthcare sector, the role of CFOs is evolving beyond traditional financial oversight to encompass broader strategic involvement. This shift necessitates a reevaluation of the support systems available to finance teams, which may not have been designed to accommodate the expanded responsibilities of modern CFOs. Key areas identified where CFOs feel unprepared include consumer affordability, patient care strategy, and technology transformation, particularly in the context of adopting emerging technologies like artificial intelligence. The survey indicates that the most pronounced readiness gap exists in consumer affordability, where 74% of CFOs are expected to engage, yet only 41% feel well-prepared. In contrast, the technology sector shows a smaller gap, with 64% of CFOs expected to participate and 48% feeling equipped. As healthcare organizations continue to invest in AI and other technologies, the need for CFOs to play a pivotal role in these decisions will likely increase, potentially widening the existing gaps if support systems do not evolve accordingly. Deloitte's findings suggest that the historical structures supporting finance functions may not align with the current demands placed on CFOs. Without necessary adjustments to reporting structures and data environments, finance leaders may struggle to influence enterprise decisions effectively, which could have significant implications for healthcare organizations navigating complex economic landscapes.

As lab results become accessible to patients almost immediately through online portals, many are seeking assistance from AI chatbots to interpret their findings. This trend is driven by the desire for instant information, with approximately 96% of patients expressing a preference for immediate access to their medical records. However, healthcare leaders must recognize the limitations of consumer AI tools, which often lack the comprehensive clinical context necessary for accurate interpretation. These tools may misrepresent results, leading to confusion and potential miscommunication during subsequent clinical visits. The reliance on AI for interpreting lab results raises significant concerns regarding the accuracy of the information provided. Studies indicate that AI models can either overstate or understate findings, which can mislead patients who may not have the medical knowledge to discern the validity of the information. Furthermore, the authoritative tone of AI responses can make incorrect answers seem credible, complicating the clinician-patient relationship when these misunderstandings carry over into consultations. Additionally, the use of public AI tools poses privacy risks, as sensitive health information may be transmitted outside of secure healthcare systems. This raises critical questions about data governance and patient trust, as healthcare organizations must navigate the balance between providing timely information and protecting patient privacy. To address these challenges, healthcare providers are encouraged to enhance their communication channels by integrating AI-assisted explanations that are grounded in the patient's medical history and securely managed within their systems. By doing so, organizations can offer timely, context-aware responses that maintain patient trust and ensure the integrity of clinical data management.

Complete Health, a primary care provider operating in Florida, Alabama, and Colorado, has agreed to pay $14.1 million to settle allegations of Medicare fraud. The settlement, announced by the Department of Justice (DOJ), resolves a whistleblower lawsuit claiming that Complete Health submitted false diagnosis codes for its senior patients to inflate reimbursements from the Medicare Advantage (MA) program between 2020 and 2023. This case highlights ongoing concerns about fraudulent practices in the MA sector, particularly as the program expands and incurs greater costs to taxpayers. The DOJ's settlement underscores the government's commitment to addressing profiteering in Medicare Advantage, a program that has faced scrutiny for its financial sustainability. Medicare pays insurers a fixed monthly amount per member, which is adjusted based on the health needs of enrollees. This system creates incentives for organizations to exaggerate health conditions, a practice known as upcoding, which is expected to result in an additional $22 billion in MA spending this year compared to traditional Medicare, according to the Medicare Payment Advisory Commission (MedPAC). Complete Health, founded in 2018, operates on a shared-risk basis with MA organizations, receiving a portion of the reimbursement for the patients it treats. The whistleblower, Karen Bowers, alleged that Complete Health engaged in upcoding for conditions such as opioid use disorder and major depressive disorder. As part of the settlement, Bowers will receive approximately $2.5 million under the whistleblower provisions of the False Claims Act. The DOJ's Assistant Attorney General emphasized the importance of holding providers accountable for improper profit-seeking at taxpayers' expense. As the Medicare Advantage program continues to grow, the Centers for Medicare & Medicaid Services (CMS) has intensified audits and implemented reforms to ensure accurate reporting of health needs. However, some proposed changes to enhance payment accuracy were not adopted, raising concerns about the effectiveness of current measures against fraud in the system.

The Trump administration has announced a new initiative to implement rebates in the 340B drug discount program, set to begin in 2027. This marks the second attempt to introduce such a system, following a previous pilot proposal that was halted earlier this year due to legal challenges. The Health Resources and Services Administration (HRSA) stated that certain discounts under the 340B program will now be provided as rebates rather than upfront savings, a move that has drawn significant backlash from hospitals and healthcare providers. The 340B program, designed to assist healthcare providers serving low-income populations, has seen its spending surge to approximately $100 billion, with a more than 600% increase in qualifying providers since 2000. The proposed rebate system is part of a broader effort to address concerns that the program has evolved into a complex and costly system, with drug manufacturers arguing that it has been misused by providers. The Inflation Reduction Act, enacted in 2022, allows Medicare to negotiate prices for certain drugs, which will include a list of 25 medications, such as Ozempic and Eliquis, subject to maximum fair prices in 2026 and 2027. Opposition from the American Hospital Association (AHA) and other stakeholders has been vocal, with claims that the rebate approach could impose additional burdens on already financially strained hospitals. Critics argue that the previous attempts to implement rebates were flawed and likely violated federal administrative law, as determined by federal courts. The AHA's CEO, Rick Pollack, emphasized that the administration's analysis significantly underestimates the potential costs and impacts on patient care. As the healthcare community braces for the implications of this new proposal, it remains to be seen how the legal landscape will evolve and whether hospitals will successfully challenge the implementation of the rebate system. The ongoing debate highlights the tension between drug manufacturers and healthcare providers over the management and sustainability of the 340B program.

Centene Corporation has reported a significant turnaround in its financial performance for the second quarter of 2023, posting a profit of $1.1 billion on revenues of $53.6 billion, marking a 10% increase year-over-year. This improvement comes after a loss of $253 million in the same quarter last year, attributed to unexpected medical spending. The managed care company has raised its financial outlook for 2026, now projecting adjusted earnings per share to exceed $4.80, a substantial increase from the previous estimate of $3.40. This positive shift is largely due to better management of medical costs and increased premiums, particularly in its Affordable Care Act (ACA) business, which has historically been a drag on earnings. Despite a decline in ACA membership by nearly 2.4 million, leaving approximately 3.5 million enrollees, the remaining members are more profitable, as evidenced by a reduction in the commercial medical loss ratio from 90.6% to 79.2%. Centene's ACA business is expected to yield a margin of 4.5% to 5% in 2026, reflecting a recovery from previous challenges. However, the company anticipates further membership losses due to rising premiums and ongoing program integrity efforts by the Trump administration, which may lead to unexpected shifts in acuity. In addition to its ACA performance, Centene has experienced membership reductions in its Medicaid program, losing over 700,000 members year-over-year, now totaling 12.1 million enrollees. This decline is attributed to state-level adjustments in Medicaid eligibility. Nevertheless, Centene has improved its medical cost management, with a medical loss ratio of 93.9% in Medicaid, down from 94.9% the previous year. The company is preparing for potential volatility due to upcoming Medicaid cuts and new work requirements that could affect millions of Americans. As Centene navigates these challenges, it remains focused on stabilizing its ACA business and managing its Medicaid operations effectively. The company is actively working with states to mitigate membership disruptions while maintaining a cautious outlook on the impact of policy changes on its financial health.